Drugs / therapeutic autologous dendritic cells
therapeutic autologous dendritic cells
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT01826877 | Jan 2013 → Jul 2018 | clear cell renal carcinoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00963521 | Jun 2008 → May 2011 | leukemia | Institut Paoli-Calmettes | Completed | No outcome recorded |
| Phase 1 | NCT00639639 | Feb 2006 → Apr 2017 | malignant glioma | Gary Archer Ph.D. | Completed | No outcome recorded |
| Phase 1 | NCT00128622 | Sep 2005 → Mar 2007 | breast cancer, colorectal cancer, lung cancer, malignant pancreatic neoplasm | H. Kim Lyerly | Completed | No outcome recorded |
| Phase 1 | NCT00098917 | Feb 2005 → ? | lung cancer | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00107211 | Jan 2005 → Jul 2008 | breast cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00107185 | Jan 2005 → Oct 2009 | central nervous system neoplasm | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00100971 | Apr 2004 → Mar 2007 | leukemia | Boston Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00085488 | Feb 2004 → Feb 2006 | cutaneous melanoma | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00023985 | Jan 2001 → Jul 2003 | lung cancer | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00005992 | Dec 2000 → ? | prostate cancer | Jonsson Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 1 | NCT00005816 | Feb 2000 → Aug 2002 | renal cell carcinoma | Duke University | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT03942328 | Sep 2019 → Aug 2030 expected | hepatocellular carcinoma, intrahepatic cholangiocarcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03325101 | Nov 2017 → Jun 2020 | cutaneous melanoma | Mayo Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00126685 | Apr 2005 → ? | cutaneous melanoma | Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen | Unknown | No outcome recorded |
| Phase 1/2 | NCT00012064 | Jul 2000 → Apr 2011 | cutaneous melanoma | Lisata Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT05518032 | Oct 2024 → Oct 2026 | colorectal carcinoma | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT00814892 | Jan → Dec 2009 | prostate cancer | Mayo Clinic | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00436930 | Dec 2006 → Oct 2012 | cutaneous melanoma | Hoag Memorial Hospital Presbyterian | Completed | No outcome recorded |
| Phase 2 | NCT00499083 | May 2006 → Jul 2009 | breast cancer | University of Nebraska | Completed | No outcome recorded |
| Phase 2 | NCT00266110 | Dec 2005 → Feb 2013 | breast cancer | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00103142 | Feb 2005 → Jun 2009 | colorectal cancer, metastatic malignant neoplasm | Michael Morse, MD | Completed | No outcome recorded |
| Phase 2 | NCT00093522 | Aug 2004 → ? | kidney cancer | St. Luke's Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00085397 | Mar 2004 → ? | cutaneous melanoma | Dana-Farber Cancer Institute | Unknown | No outcome recorded |
| Phase 2 | NCT00088985 | Jan 2004 → Oct 2009 | breast cancer | UNC Lineberger Comprehensive Cancer Center | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00027599 | Dec 2001 → Jul 2007 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00001827 | Jul 1999 → Dec 2007 | ovarian neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00001566 | Dec 1996 → Sep 2008 | Ewing sarcoma, rhabdomyosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | therapeutic autologous dendritic cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00814892 ↗ |
| Known as | CMV-DC vaccine | “Patients receive CMV-DC vaccine as in arm I.” NCT00639639 ↗ |
| Known as | DCV | “patient-specific autologous dendritic cell vaccines (DCV)” PMID 32316978 ↗ Apr 2020 |
| Known as | Renal tumor RNA-transfected dendritic cells | “Renal tumor RNA-transfected dendritic cells were administered to 10 evaluable study patients” PMID 12727829 ↗ May 2003 |
| Action | Deplete | “Vaccines made from a person's tumor cells and white blood cells may make the body build an immune response to kill tumor cells.” NCT00023985 ↗ |
| Modality | Vaccine | “initial priming peptide-pulsed antigen presenting cell (APC) vaccine is performed” NCT00001566 ↗ |
| Route | Other | “injection” NCT00001566 ↗ |